Logo

Nanogen's Shares Transferred to Pink Sheets

Mar 23, 2009

NEW YORK (GenomeWeb News) – Nanogen's shares began trading on the OTC Pink Sheets this morning after being removed from the Nasdaq market.

The transfer of the firm's common stock was expected after it announced a week and a half ago that it had received a delisting notice, which it did not intend to appeal.

As reported a week ago by GenomeWeb Daily News, Nanogen was subject to delisting because it has not paid certain outstanding fees as required for continued listing on the exchange. The firm also mentioned at the time that it had received a notice of default from General Electric related to the financing of certain equipment operated by Nanogen. The firm had failed to make certain scheduled principal and interest payments to GE under an agreement signed in June 2001.

Filed under

Elitech
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.